Browsing by title
Now showing items 1454-1473 of 4595
-
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
(AMER MEDICAL ASSOC, 2022-05-01)IMPORTANCE: Angiosarcoma is a rare sarcoma subtype with a poor outcome. Carotuximab plus pazopanib produced a median progression-free survival (PFS) of 7.8 months in pazopanib-naive patients with chemotherapy-refractory ... -
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
(AMER MEDICAL ASSOC, 2023-05-01)IMPORTANCE: Patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC) have a poor prognosis and few therapeutic options. Preclinical studies support targeting PI3K/AKT/mTOR signaling in ... -
Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series.
(SPRINGER, 2017-01-01)BACKGROUND: The efficacy and potential toxicity of rechallenge with combination ipilimumab and nivolumab has not been described. Retreatment of patients with immune checkpoint inhibitors in the setting of prior significant ... -
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
(2016-05)Background Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with ... -
Efficacy of Eribulin in Soft Tissue Sarcomas.
(FRONTIERS MEDIA SA, 2022-03-30)Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options. Eribulin, a synthetic analogue of halichondrin B, is a potent mitotic inhibitor. A phase 3 trial of previously treated ... -
Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.
(INT INST ANTICANCER RESEARCH, 2020-12-01)BACKGROUND/AIM: Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant ... -
Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors.
(AMER CHEMICAL SOC, 2016-08-17)The human epidermal growth factor receptor 3 (HER3) is overexpressed in several cancers, being linked to a more resistant phenotype and hence leading to poor patient prognosis. Imaging HER3 is challenging owing to the ... -
Efficient and gentle delivery of molecules into cells with different elasticity via Progressive Mechanoporation.
(ROYAL SOC CHEMISTRY, 2021-06-15)Intracellular delivery of cargo molecules such as membrane-impermeable proteins or drugs is crucial for cell treatment in biological and medical applications. Recently, microfluidic mechanoporation techniques have enabled ... -
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.
(PUBLIC LIBRARY SCIENCE, 2015-09-28)Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ... -
Efficient Online 4D Magnetic Resonance Imaging
(IEEE COMPUTER SOC, 2021-01-01) -
EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy - Molecular radiotherapy.
(ELSEVIER SCI LTD, 2023-12-01)The European Council Directive 2013/59/Euratom (BSS Directive) includes optimisation of treatment with radiotherapeutic procedures based on patient dosimetry and verification of the absorbed doses delivered. The present ... -
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
(BMJ PUBLISHING GROUP, 2020-11-16)OBJECTIVE: Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome ... -
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
(AMER ASSOC CANCER RESEARCH, 2020-08-01)Most patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) experience clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer bearing the same mutation rarely respond. To ... -
EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma.
(MDPI, 2022-01-13)Recurrent epidermal growth factor receptor (EGFR)-activating mutations have been identified in a rare form of head and neck cancer known as sinonasal squamous cell carcinoma (SNSCC), a malignant disease with a 5-year ... -
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.
(NATURE PUBLISHING GROUP, 2017-12-11)Transport of macromolecules through the nuclear pore by importins and exportins plays a critical role in the spatial regulation of protein activity. How cancer cells co-opt this process to promote tumorigenesis remains ... -
EGFR signaling in invasion, angiogenesis and metastasis
(Humana Press, 2008-09-25)Tumour invasion and metastasis are the hallmarks of advanced stage cancer and are associated with poor patient prognosis. EGFR is overexpressed in a variety of tumour types and this frequently correlates with a more ... -
Eighty per cent more patients in 10 years of UK molecular radiotherapy: Internal Dosimetry Users Group survey results from 2007 to 2017.
(LIPPINCOTT WILLIAMS & WILKINS, 2019-07-01) -
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
(NATURE PORTFOLIO, 2022-11-29)The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable investigational SERD ...